267 related articles for article (PubMed ID: 32455477)
1. Development and validation of an explainable artificial intelligence-based decision-supporting tool for prostate biopsy.
Suh J; Yoo S; Park J; Cho SY; Cho MC; Son H; Jeong H
BJU Int; 2020 Dec; 126(6):694-703. PubMed ID: 32455477
[TBL] [Abstract][Full Text] [Related]
2. The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator.
Parekh S; Ratnani P; Falagario U; Lundon D; Kewlani D; Nasri J; Dovey Z; Stroumbakis D; Ranti D; Grauer R; Sobotka S; Pedraza A; Wagaskar V; Mistry L; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Martini A; Picker W; Haug E; Cormio L; Nordström T; Briganti A; Boström PJ; Carrieri G; Haines K; Gorin MA; Wiklund P; Menon M; Tewari A
Eur Urol Open Sci; 2022 Jul; 41():45-54. PubMed ID: 35813258
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of prostate cancer diagnosis by machine learning techniques: an algorithm development and validation study.
Chiu PK; Shen X; Wang G; Ho CL; Leung CH; Ng CF; Choi KS; Teoh JY
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):672-676. PubMed ID: 34267331
[TBL] [Abstract][Full Text] [Related]
4. Artificial intelligence for the diagnosis of clinically significant prostate cancer based on multimodal data: a multicenter study.
Zhang H; Ji J; Liu Z; Lu H; Qian C; Wei C; Chen S; Lu W; Wang C; Xu H; Xu Y; Chen X; He X; Wang Z; Zhao X; Cheng W; Chen X; Pang G; Yu G; Gu Y; Jiang K; Xu B; Chen J; Xu B; Wei X; Chen M; Chen R; Cheng J; Wang F
BMC Med; 2023 Jul; 21(1):270. PubMed ID: 37488510
[TBL] [Abstract][Full Text] [Related]
5. Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone.
Liu J; Dong B; Qu W; Wang J; Xu Y; Yu S; Zhang X
Sci Rep; 2020 Mar; 10(1):5157. PubMed ID: 32198373
[TBL] [Abstract][Full Text] [Related]
6. An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study.
Pantanowitz L; Quiroga-Garza GM; Bien L; Heled R; Laifenfeld D; Linhart C; Sandbank J; Albrecht Shach A; Shalev V; Vecsler M; Michelow P; Hazelhurst S; Dhir R
Lancet Digit Health; 2020 Aug; 2(8):e407-e416. PubMed ID: 33328045
[TBL] [Abstract][Full Text] [Related]
7. Interactive Explainable Deep Learning Model Informs Prostate Cancer Diagnosis at MRI.
Hamm CA; Baumgärtner GL; Biessmann F; Beetz NL; Hartenstein A; Savic LJ; Froböse K; Dräger F; Schallenberg S; Rudolph M; Baur ADJ; Hamm B; Haas M; Hofbauer S; Cash H; Penzkofer T
Radiology; 2023 May; 307(4):e222276. PubMed ID: 37039688
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
[TBL] [Abstract][Full Text] [Related]
9. Development and head-to-head comparison of machine-learning models to identify patients requiring prostate biopsy.
Yu S; Tao J; Dong B; Fan Y; Du H; Deng H; Cui J; Hong G; Zhang X
BMC Urol; 2021 May; 21(1):80. PubMed ID: 33993876
[TBL] [Abstract][Full Text] [Related]
10. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Properties of Total and Free Prostate-Specific Antigen to Predict Overall and Clinically Significant Prostate Cancer Among Men With Low Testosterone and Prior Negative Biopsy.
Schwarzman LS; Pagani RL; Ohlander SJ; Mima M; Abern MR; Andriole GL; Freedland SJ; Moreira DM
Urology; 2020 Mar; 137():97-101. PubMed ID: 31733275
[TBL] [Abstract][Full Text] [Related]
12. Predicting Positive Repeat Prostate Biopsy Outcomes: Comparison of Machine Learning Approaches to Identify Key Parameters and Optimal Algorithms.
Zhang X; Feng C; Bai X; Peng X; Guo Q; Chen L; Xue J
Arch Esp Urol; 2023 Sep; 76(7):494-503. PubMed ID: 37867334
[TBL] [Abstract][Full Text] [Related]
13. [The clinical decision-making value of prostate specific antigen and its derived indicators in prostate imaging reporting and data system version 2 3 lesions].
Yang S; Zhang YY; Zhao WL; Wei CG; Chen T; Li MJ; Tan SX; Shen JK
Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(13):997-1001. PubMed ID: 32294856
[No Abstract] [Full Text] [Related]
14. Prostate Cancer Risk Prediction and Online Calculation Based on Machine Learning Algorithm.
Wang C; Chang QX; Wang XM; Wang KY; Wang H; Cui Z; Li CP
Chin Med Sci J; 2022 Sep; 37(3):210-217. PubMed ID: 36321176
[TBL] [Abstract][Full Text] [Related]
15. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
16. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
[TBL] [Abstract][Full Text] [Related]
17. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
[TBL] [Abstract][Full Text] [Related]
18. A smart, practical, deep learning-based clinical decision support tool for patients in the prostate-specific antigen gray zone: model development and validation.
Song SH; Kim H; Kim JK; Lee H; Oh JJ; Lee SC; Jeong SJ; Hong SK; Lee J; Yoo S; Choo MS; Cho MC; Son H; Jeong H; Suh J; Byun SS
J Am Med Inform Assoc; 2022 Oct; 29(11):1949-1957. PubMed ID: 36040195
[TBL] [Abstract][Full Text] [Related]
19. A risk calculator to inform the need for a prostate biopsy: a rapid access clinic cohort.
Jalali A; Foley RW; Maweni RM; Murphy K; Lundon DJ; Lynch T; Power R; O'Brien F; O'Malley KJ; Galvin DJ; Durkan GC; Murphy TB; Watson RW
BMC Med Inform Decis Mak; 2020 Jul; 20(1):148. PubMed ID: 32620120
[TBL] [Abstract][Full Text] [Related]
20. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
